Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1097 of 6351
-
Frozen hope: new study aims to help boys become fathers after cancer
Disease control Recruiting nowThis protocol is being designed to offer testicular tissue cryopreservation to male pediatric patients (0-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may cause loss of reproductive potential.
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Rare cancer hope: immune drug shows promise in phase 2 trial
Disease control OngoingThis phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block specific proteins found on white blood cells which m…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a modified enzyme starve Hard-to-Treat blood cancers?
Disease control CompletedThis is the first study of the safety of increasing dose levels of AEB1102 in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels a…
Phase 1 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New Bladder-Sparing cocktail aims to beat cancer without surgery
Disease control OngoingThis trial is to assess the efficacy of pembrolizumab (MK3475) added to concurrent radiation and gemcitabine in the management of patients with muscle-invasive urothelial cancer who are not candidates for or decline radical cystectomy.
Phase 2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New brain monitoring method may predict injury in tiniest newborns
Knowledge-focused CompletedExtremely low birth weight (ELBW), birth weight less than or equal to 1000 g, infants are at high risk for developing brain injury in the first week of life. Intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL) are the most common injuries in this group of inf…
Sponsor: Baylor College of Medicine • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New combo shows promise for hard-to-treat ovarian cancer
Disease control CompletedThe purpose of the study is to evaluate the efficacy and toxicity of apatinib in patients with platinum resistant or refractory ovarian cancer when combined with etoposide.
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New study tests Scope-Based cancer removal as surgery alternative
Disease control Recruiting nowMulticentre cohort study on the use of endoscopic submucosal dissection for the treatment of early gastrointestinal neoplasia.
Sponsor: Portsmouth Hospitals NHS Trust • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New transplant recipe may tame Graft-Versus-Host disease in blood cancer patients
Disease control OngoingThis phase II trial studies the side effect of busulfan, fludarabine phosphate, and post-transplant cyclophosphamide in treating patients with blood cancer undergoing donor stem cell transplant. Drugs used in chemotherapy, such as busulfan, fludarabine phosphate and cyclophospham…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Personalized medicine trial for kids with Hard-to-Treat cancers
Knowledge-focused Recruiting nowThis proof-of-concept platform trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe (Geoerger 2017; Geoerger 2019). The aims of the trial are: 1. To determine the recomme…
Phase 1/2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Reading the Body's stress signal from the skin
Knowledge-focused By invitation onlyThere are many sympathetic hyperactivity diseases in the investigators' clinical practice. However, the conventional method to measure the sympathetic nerve activity had many limitations such as clinical application, data interpretation and even therapeutic manipulation. Therefor…
Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New injection shows promise for postpartum depression
Symptom relief CompletedThe purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 micrograms per kilogram per hour (μg/kg/h) for 60 hours reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo injection as assessed…
Phase 3 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
New Scan-Guided proton therapy aims to stop rare bone tumors
Disease control CompletedImproved local control of chordoma initially treated with surgery or not, thanks to adjuvant radiotherapy oriented by conventional imaging Computed Tomography /Magnetic Resonance Imaging (CT / MRI) and guided by the \[18Fluor\] (\[18F\]) Fluoroazomycin Arabinofuranoside (FAZA) Po…
Phase 2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Targeted drug crizotinib tested on rare Gene-Mutated cancers
Disease control OngoingThis phase II MATCH treatment trial tests how well crizotinib works to treat patients with cancers with MET exon 14 deletion genetic changes. Crizotinib is in a group of medications called tyrosine kinase inhibitors. It works by blocking enzymes that cancer cells need to grow and…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope: drug before surgery may shrink ovarian tumors
Disease control OngoingThis is a study that will look at the effects and how useful investigational drug olaparib is as a neoadjuvant treatment (treatment given as to shrink a tumor before the main treatment) prior to surgery in patients with recurrent ovarian, primary peritoneal or fallopian tube canc…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Triple threat: new combo aims to stop pancreatic cancer spread
Disease control CompletedThis study will be looking at whether combining cyclophosphamide, pembrolizumab (an antibody that blocks negative signals to T cells), GVAX (pancreatic cancer vaccine), and SBRT (focused radiation) is effective (anti-tumor activity) and safe in patients with locally advanced panc…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control OngoingThis phase II trial studies how well trametinib and docetaxel work in treating patients with stage IV KRAS mutation positive non-small cell lung cancer or cancer that has come back. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell grow…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New radiation therapy shows promise for slowing neuroendocrine tumors
Disease control OngoingThis is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has p…
Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a pacemaker tame stubborn high blood pressure?
Disease control Stopped earlyThe purpose of this double blind randomized study is the evaluation of the safety and efficacy of the Moderato System. The Moderato implantable pulse generator is indicated for patients who have hypertension and also require a dual chamber pacemaker in order to reduce their bloo…
Sponsor: BackBeat Medical Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Precision radiation may offer better pain relief for spine metastases
Symptom relief CompletedThis study will compare pain (primary end-point) and local metastatic tumor control (secondary end-point) after dose-intensified image-guided fractionated stereotactic body radiation therapy (SBRT) for painful mass-type spinal metastases versus conventional radiation therapy.
Phase 2 • Sponsor: University of Zurich • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Immunotherapy drug may delay cancer's return after surgery
Disease control OngoingThe purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with squamous cell cancer of the head and neck remains disease-free following locoregional disease recurrence.
Phase 2 • Sponsor: Assuntina G. Sacco, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC